Sort
48,018 grants matching “immunotherapy”
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
$560,248Bin Zhang · Northwestern University At Chicago · R01 · FY2023 · CA
3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation
$560,211Joseph F Costello · University Of California, San Francisco · R01 · FY2023 · CA
3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation
$560,211Joseph F Costello · University Of California, San Francisco · R01 · FY2022 · CA
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer
$560,049Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2023 · CA
Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia
$560,038Nicholas Chiorazzi · Feinstein Institute For Medical Research · R01 · FY2021 · CA
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
$560,034Elias Sayour · University Of Florida · R01 · FY2022 · CA
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
$560,030Jun Wang · New York University School Of Medicine · R37 · FY2023 · CA
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
$560,015Henrieta Scholtzova · New York University School Of Medicine · R01 · FY2018 · NS
Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC)
$559,976Anirban Maitra · University Of Tx Md Anderson Can Ctr · U24 · FY2020 · CA
Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC)
$559,976Anirban Maitra · University Of Tx Md Anderson Can Ctr · U24 · FY2021 · CA
Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer
$559,846Gerald V Denis · Boston University Medical Campus · R01 · FY2018 · CA
The interplay of social and molecular determinants in lung cancer disparity
$559,834Shailesh Singh · Morehouse School Of Medicine · R01 · FY2024 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$559,834David P Carbone · Ohio State University · R01 · FY2022 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer
$559,757Maximilian Diehn · Stanford University · R01 · FY2024 · CA
Restoring the Immunogenicity of Head and Neck Cancer
$559,720Yu Leo Lei · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · DE
Notch Signaling in the Adult Lymphatic Vasculature
$559,718Carrie J. Shawber · Columbia University Health Sciences · R01 · FY2024 · HL
Image-based models of tumor-immune dynamics in glioblastoma
$559,690Leland Hu · Mayo Clinic Arizona · U01 · FY2025 · CA
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
$559,672Yoon Yeo · Purdue University · R01 · FY2024 · CA
Antigenic Determinants on HLA-B7 and -A2
$559,645Victor H. Engelhard · University Of Virginia · R01 · FY2011 · CA
Project-003
$559,613Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2020 · CA
CAREER: Engineered tumor models to study the recruitment and activation of Natural Killer cells
$559,500Blanka Sharma · University Of Florida · · FY2019 · ENG
Antigenic Determinants on HLA-B7 and -A2
$559,343Victor H. Engelhard · University Of Virginia · R01 · FY2012 · CA
Immunologic Responses to Cow's Milk Proteins in IgE-mediated Cow's Milk Allergy
$559,165Hugh Sampson · Icahn School Of Medicine At Mount Sinai · U19 · FY2012 · AI
CD200R blockade for cancer immunotherapy
$559,062Sujit Basu · Ohio State University · R01 · FY2024 · CA
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)
$559,059Carston R. Wagner · University Of Minnesota · R01 · FY2023 · CA